A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia

Trial Profile

A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary) ; Cyclophosphamide
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takara Bio
  • Most Recent Events

    • 11 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 19 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top